Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design
- 69 Downloads
Background and Aims
Diabetes mellitus (DM) can cause left ventricular (LV) diastolic dysfunction, leading to heart failure with preserved ejection fraction (HFpEF). Dipeptidyl peptidase IV (DPP-IV) inhibitors have failed to reduce hospitalization due to HF in type 2 DM (T2D) patients in a large-scale clinical trial, despite their cardiovascular protective effects. Therefore, it is important to investigate whether DPP-IV inhibitors can improve LV diastolic dysfunction in T2D patients. The aim of the study was to evaluate whether teneligliptin, the strongest of the DPP-IV inhibitors, improves LV dysfunction or prevents the worsening of LV diastolic function in T2D patients.
The TOPLEVEL study is designed as an open-labeled, marker-stratified randomized, parallel-group comparison, standard treatment-controlled multicenter study. TOPLEVEL includes two marker-defined subgroups to give treatment recommendations for T2D patients with normal (E/e′ < 8) or impaired LV diastolic function (E/e′ ≥ 8), where E/e′ is the ratio of peak velocity of early transmitral diastolic filling by echocardiography to early diastolic mitral annular velocity by tissue Doppler echocardiography as LV diastolic function. Patients are randomly assigned to either teneligliptin (20 or 40 mg) or the standard treatment group. All patients are followed up for 2 years. The primary endpoint measure is the change in E/e′ from baseline and 2 years after enrollment.
Conclusion and Perspectives
TOPLEVEL is a clinical trial of teneligliptin targeting LV diastolic dysfunction in T2D patients. This study demonstrates the effectiveness of DPP-IV inhibitors on LV diastolic dysfunction, an important surrogate endpoint to predict the cardiovascular outcomes of HFpEF (UMIN000014589).
KeywordsLeft ventricular diastolic dysfunction Type 2 diabetes mellitus DPP-IV inhibitors Teneligliptin
We gratefully acknowledge Ms. M. Yoda, Ms. M. Takahashi, Ms. R. Umezawa, and Ms. M. Saida for their secretarial assistance.
MI conceived the study. MI and SI wrote the manuscript. TH performed statistical analyses and provided the biostatistical study design. MK conceived and supervised the study and is the Principal Investigator on the grant. All authors read and approved the final manuscript.
Sources of Funding
This study was conducted with funding provided by the Mitsubishi Tanabe Pharma Corporation.
Compliance with Ethical Standards
Conflict of Interest
Persons from Mitsubishi Tanabe Pharma Corporation were not involved in conducting this study and analysis, and the intentions of Mitsubishi Tanabe Pharma Corporation are not reflected in the results or interpretations of this study.
Drs. Imadu, Ito, and Hamasaki have nothing to disclose. Dr. Nakano is now an employee of GlaxoSmithKline K.K. Dr. Kitakaze reports receiving grants from the Japanese government during the course of the study: grants from the Japanese government, grants from the Japan Heart Foundation, grants from the Japan Cardiovascular Research Foundation, grants and personal fees from Asteras, personal fees from Daiichi-sankyo, grants and personal fees from Pfizer, grants and personal fees from Ono, personal fees from Bayer, grants from Novartis, grants and personal fees from Mitubishi Tanabe Pharma, personal fees from Kowa, personal fees from MSD, grants from Nihon Kohden, personal fees from Shionogi, personal fees from AstraZeneca, grants and personal fees from AstraZeneca, personal fees from Taisho-Toyama, personal fees from Toyama-Kagaku, grants and personal fees from Kureha, and personal fees from Toaeiyo, outside of the currently proposed work.
- 27.Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102(15):1788–94.CrossRefGoogle Scholar
- 30.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.CrossRefGoogle Scholar
- 32.Ihara M, Asanuma H, Yamazaki S, Kato H, Asano Y, Shinozaki Y, et al. An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2015;308(10):H1287–97.CrossRefGoogle Scholar
- 33.Aoyama M, Kawase H, Bando YK, Monji A, Murohara T. Dipeptidyl peptidase 4 inhibition alleviates shortage of circulating glucagon-like Peptide-1 in heart failure and mitigates myocardial remodeling and apoptosis via the exchange protein directly activated by cyclic AMP 1/Ras-related protein 1 Axis. Circ Heart Fail. 2016;9(1):e002081.CrossRefGoogle Scholar